Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL27792846 | 0.98 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Piperazine SCHEMBL28654365 | 0.95 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28024376 | 0.93 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28224693 | 0.91 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Piperidine SCHEMBL4124279 | 0.89 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Piperidine SCHEMBL27915255 | 0.87 | ALDH1A1 (0.58) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28544456 | 0.84 | — | — | |
| Ethyl Acetate SCHEMBL27910917 | 0.84 | — | — | |
| Ethyl Acetate SCHEMBL28110884 | 0.84 | — | — | |
| Ethyl Acetate SCHEMBL30152067 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | disclosed |
| CN-102212054-B | Fluorescence analysis preparation, method for preparing same and application thereof | CHINESE ACAD INST CHEMISTRY | 2013-12-11 | — | — | CN | disclosed |
| CN-103214473-A | Dibenzo[b,f][1,4]oxazapine compounds | ARYX THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| CN-102212054-A | Fluorescence analysis preparation, method for preparing same and application thereof | CHINESE ACAD INST CHEMISTRY | 2011-10-12 | — | — | CN | disclosed |
| CN-101821251-A | Chiral cis-imidazolines | HOFFMANN LA ROCHE | 2010-09-01 | — | — | CN | disclosed |
| CN-101641350-A | Dibenzo [ b ] | ARYX THERAPEUTICS INC US | 2010-02-03 | — | — | CN | disclosed |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PACHECO, OGARI (BR) | 2004-06-03 | — | — | US | disclosed |
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1439005-A | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1315729-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristalia Produtos Quimicos e Farmaceuticos Ltda (BR) | 2003-06-04 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002012241-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristália Produtos Químicos e Farmacêuticos Ltda. (BR) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| CN-1228087-A | Substituted pyrimidine derivatives and their pharmaceutical use | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PEPD, PREP, PAPSS1 | ALDH1A1 2739/4885LMNA 369/4885HSD17B10 1362/4885 |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | ALDH1A1 2226/4885LMNA 2449/4885HSD17B10 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.